Author

J. Millul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

D. Neri· 4 shared S. Cazzamalli· 4 shared A. Zana· 3 shared A. Galbiati· 2 shared A. Villa· 2 shared A. Elsayed· 1 shared B. Gouyou· 1 shared C. Krudewig· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

D. Neri

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates

E. Gilardoni, A. Zana, A. Galbiati, T. Sturm, J. Millul, S. Cazzamalli, D. Neri, R. Stucchi

The paper develops a mass spectrometry-based method to quantify tumor-targeting small molecule-metal conjugates and validates it against radioactive biodistribution data.

bioRxiv · Mar 4, 2022Pharmacology & Toxicology

A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake

A. Galbiati, A. Zana, M. Bocci, J. Millul, A. Elsayed, J. Mock, D. Neri, S. Cazzamalli

This paper develops a dimeric FAP-targeting radioligand with prolonged tumour uptake and improved tumour-to-organ ratio, showing potent anti-tumour efficacy in preclinical models.

bioRxiv · Feb 21, 2022Pharmacology & Toxicology

Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate

B. Gouyou, J. Millul, A. Villa, S. Cazzamalli, D. Neri, M. Matasci

This paper develops a tumor-targeting cytokine conjugate using Sortase A-mediated site-specific modification of interleukin-2 with acetazolamide, targeting carbonic anhydrase IX.

bioRxiv · Jul 20, 2020Bioengineering

Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX

J. Millul, C. Krudewig, A. Zana, S. Dakhel Plaza, E. Puca, A. Villa, D. Neri, S. Cazzamalli

This study shows that combining SMDCs targeting carbonic anhydrase IX with immunotherapy enhances anticancer activity in mouse models of renal cell carcinoma and colorectal cancer.

bioRxiv · Jun 3, 2020Cancer Biology